Evaluation of near-infrared fluorescence (NIRF) imaging for sentinel lymph node (SLN) detection in squamous cell carcinoma of the vulva: a feasibility study

Evaluation of near-infrared fluorescence (NIRF) imaging for sentinel lymph node (SLN) detection in squamous cell carcinoma of the vulva: a feasibility study - Sentinel node detection in vulvar cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33082

Enrollment

Registered

2009-06-12

Start date

2009-06-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sentinel lymph node vulvar carcinoma

Interventions

Injection of ICG together with patent blue (golden standard)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: female > 21 yrs of age with biopsy proven squamous cell carcinoma of the vulva who are eligible for a sentinel node procedure

Exclusion criteria

Exclusion criteria: Pregnant women, significant renal (creatinine > 110 ug/l), cardiac, or pulmonary disease (ASA III-IV), History of iodine allergy or anaphylactic reactions to insect bites or medication, presence or history of hyperthyroidism.

Design outcomes

Primary

Measure	Time frame
the number and localisation of sentinel lymph node(s) detected with the camera and ICG, compared to the detection with radiocolloid and patent blue	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)